Difei Yang
Stock Analyst at Mizuho
(1.84)
# 4,075
Out of 4,789 analysts
36
Total ratings
28.12%
Success rate
4.79%
Average return
Main Sectors:
Stocks Rated by Difei Yang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AKBA Akebia Therapeutics | Downgrades: Neutral | $6 → $2 | $1.91 | +4.71% | 4 | Mar 31, 2022 | |
| BLUE bluebird bio | Maintains: Buy | $580 → $460 | $5.25 | +8,661.90% | 3 | Sep 22, 2021 | |
| NVCR NovoCure | Maintains: Neutral | $229 → $200 | $17.52 | +1,041.55% | 6 | Jul 30, 2021 | |
| CASI CASI Pharmaceuticals | Initiates: Buy | $38 | $2.10 | +1,709.52% | 1 | Apr 26, 2021 | |
| FGEN FibroGen | Downgrades: Neutral | $29 | $0.30 | +9,563.45% | 4 | Apr 7, 2021 | |
| QURE uniQure | Upgrades: Buy | $52 | $9.91 | +424.72% | 4 | Apr 1, 2021 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | $158 → $160 | $61.91 | +158.44% | 2 | Feb 26, 2021 | |
| XERS Xeris Biopharma Holdings | Maintains: Buy | $18 → $14 | $5.08 | +175.59% | 4 | Apr 23, 2020 | |
| NKTR Nektar Therapeutics | Upgrades: Buy | $21 → $35 | $0.64 | +5,391.92% | 4 | Feb 3, 2020 | |
| BOLD Boundless Bio | Upgrades: Buy | n/a | $1.45 | - | 2 | Aug 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $28 | $6.76 | +314.20% | 1 | Feb 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $2.11 | +1,227.01% | 1 | Sep 27, 2017 |
Akebia Therapeutics
Mar 31, 2022
Downgrades: Neutral
Price Target: $6 → $2
Current: $1.91
Upside: +4.71%
bluebird bio
Sep 22, 2021
Maintains: Buy
Price Target: $580 → $460
Current: $5.25
Upside: +8,661.90%
NovoCure
Jul 30, 2021
Maintains: Neutral
Price Target: $229 → $200
Current: $17.52
Upside: +1,041.55%
CASI Pharmaceuticals
Apr 26, 2021
Initiates: Buy
Price Target: $38
Current: $2.10
Upside: +1,709.52%
FibroGen
Apr 7, 2021
Downgrades: Neutral
Price Target: $29
Current: $0.30
Upside: +9,563.45%
uniQure
Apr 1, 2021
Upgrades: Buy
Price Target: $52
Current: $9.91
Upside: +424.72%
Sarepta Therapeutics
Feb 26, 2021
Maintains: Buy
Price Target: $158 → $160
Current: $61.91
Upside: +158.44%
Xeris Biopharma Holdings
Apr 23, 2020
Maintains: Buy
Price Target: $18 → $14
Current: $5.08
Upside: +175.59%
Nektar Therapeutics
Feb 3, 2020
Upgrades: Buy
Price Target: $21 → $35
Current: $0.64
Upside: +5,391.92%
Boundless Bio
Aug 8, 2018
Upgrades: Buy
Price Target: n/a
Current: $1.45
Upside: -
Feb 13, 2018
Initiates: Neutral
Price Target: $28
Current: $6.76
Upside: +314.20%
Sep 27, 2017
Initiates: Buy
Price Target: $28
Current: $2.11
Upside: +1,227.01%